Software derives biomarkers designed to monitor respiratory disease.
Functional respiratory imaging company Fluidda secured clearance from the U.S. Food & Drug Administration (FDA) this week for its digital imaging platform, Broncholab. The product is designed to help providers visualize factors that can help diagnose respiratory disease.
“Functional respiratory imaging has been used in clinical trials for many years and has proven its value time and time again,” said Jan De Backer, Fluidda’s chief executive officer, in a statement. “Broncholab now extends these capabilities into clinical practice which is a tremendous step forward in our quest for better respiratory care.”
Used after a low-dose CT scan, Broncholab can derive several biomarkers, such as nodule and airway volume, trapped air pockets, and maps of ventilation. According to company information, it can also predict how drug particles are deposited throughout the lung when a patient breathes them in, helping to guide and maximize treatment options.
In addition to using high-resolution CT scans, the BronchoLab system incorporates digital image processing, 3D modeling, and computational airflow simulations to offer clinically relevant information about perfusion in various lung regions.
The hope, De Backer added in the company statement, is that BronchoLab will be able to improve the understanding of respiratory illnesses, better preparing the healthcare system for global outbreaks of lung diseases, much like the current COVID19 pandemic.